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Abstract
Background: Prostate cancer is characterized by heterogeneity in the clinical course that often
does not correlate with morphologic features of the tumor. Metastasis reflects the most adverse
outcome of prostate cancer, and to date there are no reliable morphologic features or serum
biomarkers that can reliably predict which patients are at higher risk of developing metastatic
disease. Understanding the differences in the biology of metastatic and organ confined primary
tumors is essential for developing new prognostic markers and therapeutic targets.
Methods: Using Affymetrix oligonucleotide arrays, we analyzed gene expression profiles of 24
androgen-ablation resistant metastatic samples obtained from 4 patients and a previously published
dataset of 64 primary prostate tumor samples. Differential gene expression was analyzed after
removing potentially uninformative stromal genes, addressing the differences in cellular content
between primary and metastatic tumors.
Results: The metastatic samples are highly heterogenous in expression; however, differential
expression analysis shows that 415 genes are upregulated and 364 genes are downregulated at least
2 fold in every patient with metastasis. The expression profile of metastatic samples reveals changes
in expression of a unique set of genes representing both the androgen ablation related pathways
and other metastasis related gene networks such as cell adhesion, bone remodelling and cell cycle.
The differentially expressed genes include metabolic enzymes, transcription factors such as
Forkhead Box M1 (FoxM1) and cell adhesion molecules such as Osteopontin (SPP1).
Conclusion: We hypothesize that these genes have a role in the biology of metastatic disease and
that they represent potential therapeutic targets for prostate cancer.
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Background
Prostate cancer is the most common cancer in men result-
ing in over 232,090 new cases and 30,350 deaths annually
[1]. For prostate cancer patients, metastatic disease reflects
the most adverse clinical outcome. Osseous involvement
with severe bone pain and spinal cord complications
occur commonly in patients with metastatic disease [2].
However there is considerable heterogeneity in outcome
after primary diagnosis and currently there are no mor-
phologic or circulating biomarkers that can accurately pre-
dict the development of metastatic disease.
Metastatic prostate cancer represents the tumor's ability to
escape from the primary organ and eventually colonize a
distant site. Disruption of a complex set of biological
processes must occur in order for tumor cells to leave the
prostate and establish themselves in a different environ-
ment. Their altered interaction with the prostate microen-
vironment, including the stroma and extracellular matrix,
their ability to migrate into the vasculature and establish
themselves in secondary organs with recruitment of vascu-
lar supply represent disruption of normal cellular proc-
esses [3]. Understanding the molecular events involved in
the development of metastatic prostate cancer has the
potential to identify biological determinants that can aid
in prognosis and development of more effective therapies.
Using gene expression microarrays, a number of studies
have characterized expression profiles of prostate cancer,
normal tissue and metastatic cancers. In some cases, cor-
relations between tumor expression signatures, clinical
parameters and outcome have been identified [4-11].
Unique profiles have been reported for untreated and
short-term androgen ablation treated organ-confined dis-
ease and for metastatic disease, with a subset of genes dif-
ferentiating metastatic androgen ablation resistant
prostate cancer (AARPC) from androgen dependent met-
astatic cancers [10,12-14]. In general, metastatic prostate
cancer is characterized by changes in expression of genes
involved in signal transduction, cell cycle, cell adhesion,
migration and mitosis. In addition to these genes, AAR-
PCs exhibit changes in expression of the androgen recep-
tor and enzymes involved in the sterol biosynthesis
pathway [12].
Some of the genes previously reported as highly downreg-
ulated in prostate tumors may reflect the differences in
cellular content of metastatic and organ-confined tissues
rather than intrinsic differences in biology. In contrast
with organ-confined prostate tumors which are composed
of a mixture of glandular epithelial, smooth muscle and
other stromal cells, metastatic tissue samples are almost
exclusively epithelial, with minimal supporting stroma
and absence of smooth muscle. In this study, we charac-
terize gene expression in androgen ablation resistant met-
astatic tumors after removing potentially uninformative
stromal genes. The deleted stromal genes consist of those
reported in a recent report characterizing the gene expres-
sion patterns in the prostate stroma, tumor and normal
epithelium [15]. Our results provide novel insights into
the biology of metastasis.
Methods
Tumor sample procurement
All tissue samples were acquired from the Health Sciences
Tissue Bank of the University of Pittsburgh Medical Center
under stringent Institutional Review Board guidelines
with appropriate informed consent. The 18 donor and 64
primary prostate tumor samples have been described pre-
viously [7]. Specimens were received directly from the
operating room. Samples (>500 mg) were excised and
snap frozen in liquid nitrogen within 30 min of excision
and stored at -80°C until extraction of RNA. Metastatic
tumor samples were obtained from a warm autopsy pro-
gram and processed similarly to primary tumors. An H&E
stained frozen section of each sample was evaluated by a
pathologist, to determine epithelial and stromal content
and verify the presence of tumor in the sample. Dissection
of the frozen tissue block was performed with the guid-
ance of a marked H & E slide to minimize the presence of
host tissue in the metastatic samples. All samples used in
the study contained >80% tumor. Metastatic tumor sam-
ples were minced and divided into two equal portions to
be extracted with the sample protocol used for each set of
primary tumors.
Clinical profile of cases
The clinical characteristics of the 64 primary tumor sam-
ples used in the Affymetrix portion of our study have been
previously described [6,7]. These cases have a mean fol-
low-up time of 3 years. The metastatic samples consisted
of 24 tissues derived from 4 patients (Table 1). All patients
with metastatic disease had received androgen ablation
therapy and had shown progression of disease while on
androgen ablation. The clinical characteristics for the
additional 10 primary prostate tumor cases used in the
CodeLink study are shown in Table 1.
RNA extraction
RNA purification for the 64 primary samples has been pre-
viously described [6]. The set of metastatic samples ana-
lyzed with the Affymetrix platform was extracted with the
same methodology. The set of metastatic samples and pri-
mary tumors analyzed with the CodeLink platform were
extracted using the RNeasy kit (Qiagen, San Diego, CA).
For the metastatic samples, one sample did not have
enough for extraction with the Qiagen method, only 23
metastatic samples are included in the CodeLink assays.
The concentration of each total RNA sample was meas-
ured with a Nanodrop ND-1000 spectrophotometerBMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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(Nanodrop Technologies,Wilmington, DE). RNA integ-
rity was determined by capillary electrophoresis using an
Agilent 2100 Bioanalyzer (Agilent, Willmington, DE).
cRNA preparation and gene expression assays
cRNA was prepared and hybridized to Affymetrix Gene-
Chip HGU95av2, HGU95b and HGU95c arrays (Affyme-
trix, Santa Clara, CA) as previously described [6]. For gene
expression profiling with the CodeLink Gene Expression
System (GE Healthcare, Piscataway, NJ), biotin-labeled
cRNA was prepared as previously described [16]. Ten
micrograms of biotin-labeled cRNA product from each
sample were then fragmented with RNA fragmentation
buffer at 94°C for 20 minutes. Hybridization mix was pre-
pared according to the manufacturer's instructions and
the final volume was adjusted to 260ul using nuclease-
free water. The hybridization mix was heat denatured at
90°C for 5 minutes, cooled on ice and then applied to
Human Uniset 20 K arrays (GE Healthcare, Piscataway,
NJ). Arrays were incubated at 37°C for 18 h with shaking
at 60 rpm in an Innova hybridization oven (New Bruns-
wick, Edison, PA).
After hybridization, arrays were placed in a pre-heated
(46°C) chamber filled with 0.75 × TNT (0.75 M Tris-HCL,
pH 7.6, 3.75 M NaCl, Tween-20, and milli-Q water) and
incubated at 46°C for 1 hour. Arrays were then stained
with Streptavidin-Alexa Fluor 647 (Molecular Probes,
Grand Island, NY) for 30 minutes at room temperature.
Upon the completion of staining, the arrays were washed
three sequential times in fresh 1 × TNT (1 M Tris-HCL, pH
7.6, 5 M NaCl, Tween-20, and milli-Q water) and then
washed two final times in fresh solutions of 0.05%
Tween-20 and 0.1 × SSC with gentle agitation. All arrays
were dried by centrifugation at 2000 rpm for 3 minutes.
Affymetrix arrays were scanned in an Affymetrix GCS3000
Scanner (Affymetrix, Santa Clara, CA). CodeLink arrays
were scanned with the GenePix 4000B scanner using
GenePix Pro 4.1 software (Molecular Devices, Sunnyvale,
CA).
Gene expression data analysis
The raw scanned array images from the Affymetrix Gene-
Chip U95 arrays were processed using GCOS 1.1 software
Table 1: Clinical variables for primary and metastatic prostate cancer samples used in this study
Prostate Cancer 
Tissue Samples
No. of Samples Number of 
Patients
Microarray 
Platform
Clinical Information
64 64 Affymetrix Please see reference [7]
Gleason Score No. of Cases
71 0
Primary Tumors 10 10 CodeLink Pathological Stage No. of Cases
2B 6
3A 3
3B 1
Patient ID No. of Samples
FB6561 11
FB666 1
FB667 8
FB669 5
Metastatic Sites No. of Samples
Metastatic 24 4 Affymetrix Liver 5
Para Aortic Lymph 
Node
3
Para Tracheal Lymph 
Node
8
Retroperitoneal 
Lymph Node
3
Lung 1
Adrenal 2BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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using the MAS5 algorithm (Affymetrix Corporation, Santa
Clara, Ca) to generate probe cel intensity (*.cel) files. Data
normalization to remove variation in overall chip intensi-
ties was performed by global scaling to a chip mean target
intensity of 200 (MAS 5.0). Data for U95Av2, B and C
arrays were combined for further analyses.
To identify differentially regulated genes in both datasets,
these were analyzed with the Significance Analysis of
Microarrays software (SAM v 1.2) [17]. Prior to analysis,
genes that showed low variation across all samples were
removed by using the filtering option in the Avadis 3.3
Pride Software (Strand Life Sciences, Bangalore, India)
data analysis tool. To avoid false results due to difference
in the tissue composition of metastatic and primary
tumors, genes identified as being highly expressed in the
prostatic stroma as per Stuart et al [15] were also removed.
In all 1506 stromal genes and 7678 invariant genes were
removed from the Affymetrix dataset. SAM generated gene
lists with the lowest false discovery rates (FDR) were fur-
ther analyzed for gene ontology (GO) and pathway anno-
tations using NIH's DAVID annotation tool [18].
For CodeLink arrays, image files were analyzed with the
CodeLink Expression Analysis Software version 4.1 (GE
HealthCare) with use of the normalized intensity values
in downstream analysis. For cross-platform comparison,
Affymetrix probe sets and Codelink identifiers were
mapped to Unigene ids using the DAVID annotation tool
(see above). Expression data from both platforms was
compared using z-transformation. Hierarchical clustering
was performed using Eisen's Cluster and Treeview [19].
Data from Affymetrix experiments has been submitted to
NCBI's Gene Expression Omnibus (GEO) as series
GSE6919, with the following accession numbers
GSE6604 (normal donor prostate), GSE6605 (metastatic
prostate tumors), GSE6606 (primary prostate tumors)
and GSE6608 (normal prostate tissue adjacent to tumor).
Data from the CodeLink platform have been submitted to
GEO with the accession number GSE6752 (primary and
metastatic prostate tumors).
Quantitative real-time PCR
Differential expression of ten genes in primary and meta-
static prostate cancer samples was verified with quantita-
tive real-time PCR (QPCR) with the ABI PRISM® 7000
sequence detection system (Applied Biosystems, Foster
City, CA). Three selected RNA samples from each patient
were pooled together (except for patient FB666 n = 1) and
therefore four RNA samples, each representing one
patient, were tested. RNA samples were first heat-dena-
tured at 70°C for 10 minutes in an Eppendorf master
cycler (Eppendorf, Westbury, NY) and then chilled imme-
diately on ice. cDNAs were reversely transcribed from one
microgram of RNA using the M-MLV Reverse Tran-
scriptase kit (Invitrogen, Carlsbad, CA), as recommended
by the manufacturer. QPCR was performed based on the
manufacturer's instructions with TaqMan Gene Expres-
sion Assays (Applied Biosystems) for the following genes:
EGR3, SYNPO2, ANGPT2, SPP1, FOXM1, ADM, RDX,
TGFBRAP1, MAK and EGR1(assay IDs: Hs00231780_m1,
Hs00326493_m1, Hs01048047_mH, Hs00959010_m1,
Hs00153543_m1, Hs00969450_g1, Hs00988414_g1;
Hs01093285_m1; Hs01048300_m1, Hs00152928_m1).
When multiple TaqMan assays for one gene were availa-
ble, the assay that interrogated the sequence closest to the
target sequence in the Affymetrix arrays was chosen. PCR
cycles were performed according to the assay instructions
in an ABI PRISM®  7000 Sequence Detection System
(Applied Biosystems). Relative quantification of the
expression level of each transcript in each sample was cal-
culated using the Delta-Delta CT method in the ABI
PRISM 7000 Sequence Detection System Software
(Applied Biosystems) [20]. Human reference RNA from
Stratagene (Stratagene Corp., La Jolla, CA) was used as the
calibrator (untreated control) and human glucuronidase
beta (GUSB) gene was used as the endogenous reference
gene (Forward primer: GGA ATT TTG CCG ATT TCA TGA;
Reverse primer: CCG AGT GAA GAT CCC CTT TTT; Probe:
6FAM-AAC AGT CAC CGA CGA GAG TGC TGG G-
TAMRA).
Results
Differential gene expression in metastatic prostate cancer 
and the role of stromal content in defining true 
downregulated genes
Differential expression analysis of the metastatic and pri-
mary tumor samples shows that a large number of the
most highly downregulated genes such as TAGLN,
ACTG2, TPM1, MYH111 and DES have been previously
identified as expressed mostly in the prostatic stromal
cells [15]. Since only the epithelial component of prostate
cancer is present in metastatic tumors, this result most
likely reflects the lack of stroma in metastases, and not a
true down-regulation of these genes in the metastatic epi-
thelial cells. Therefore, based on a recent report character-
izing cell type specific gene expression in the prostate [15],
we removed the set of genes expressed mainly by the stro-
mal cells of the primary tumors. In all 1506 transcripts
associated with a stromal signature were deleted prior to
further analysis. Since the stromal genes were character-
ized using the U95Av2 chip and our analysis includes
u95Av2, B and C chips, only stromal genes represented by
probe sets on U95Av2 were removed in this modified
analysis. SAM analysis shows that 1277 genes are up and
977 genes are downregulated at least 2 fold at the lowest
FDR (0.01), in metastatic prostate samples (see Addi-
tional file 1). A list of the top 50 up and top 50 down reg-
ulated genes at the lowest fdr, after removing ESTs and
uncharacterized clones is shown in Table 2. This listBMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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includes signal transducers, cell cycle regulators, meta-
bolic enzymes and cell adhesion molecules. Some of the
most upregulated genes in our list are EIF1AX, AR, HSPD1
and HSPCA, K-ALPHA1, MLL5, UGT2B15, and some of
the most downregulated genes include WNT5B5,
ANXA11, FOS and SFRP1.
Metastatic samples are heterogenous in gene expression
Using immunohistochemistry (IHC) Shah et al. have
shown that metastatic samples are highly heterogenous in
expression of prostate specific markers leading to the
hypothesis that at the molecular level, metastatic prostate
cancer may represent multiple diseases even within the
same patient [21]. We examined the expression of several
transcripts markers including some studied by Shah et al.
and confirmed the heterogeneity of expression levels in
metastatic prostate cancer tissues. Expression values in
donor samples, primary and metastatic samples were
compared. Prostate specific antigen (PSA/KLK3) remains
high in some metastatic samples and is low or absent in
others, even within the same patient (Figure 1). Interest-
ingly, AMACR, another biomarker for prostate cancer [22]
expresses a heterogenous expression pattern similar to
PSA.  HPN, which is overexpressed in primary cancer
maintains high expression in the metastatic samples in
our study. AR, while overexpressed in 23 out of the 24
metastatic samples, shows highly variable expression val-
ues in individual samples. The proto-oncogenes FOS and
JUNB, which are both overexpressed in primary tumors,
are consistently downregulated in all metastatic samples.
Genes regulated in all metastatic cases
Hierarchical clustering analysis reveals that gene expres-
sion in metastatic samples is more variable between
patients than between different metastatic sites from each
patient (Figure 2). Although the 24 metastatic samples
represent tissues from 6 metastatic sites (Table 1), no
organ specific clusters were detected (Figure 2) whereas
samples from the same patient tend to cluster together.
Statistical comparison of organ-specific expression pro-
files was not attempted due to unequal distribution of
samples from different metastatic sites.
In order to identify probe sets that are similarly regulated
in every patient, and therefore likely to represent a specific
metastatic profile, the SAM differentially expressed gene
list at a FDR of 2% was further filtered. For each gene on
this list, a patient specific median expression value was
calculated from the multiple samples from each patient.
Patient P4 had only sample and this sample's signal value
was considered the median value. The median values were
then compared to the median value of the primary sam-
ples and those probe sets whose median value showed
equal or more than a 2 fold change in every patient were
considered part of the metastatic prostate cancer signa-
ture. Under this criteria 415 transcripts are upregulated
and 364 are downregulated in all patients with metastasis
(see Additional file 2). A truncated gene list consisting of
genes regulated at least 3 fold in all patients is shown in
Table 3. Upregulation of AR in all samples from meta-
static cancer patients represents a known "androgen resist-
ant" or AARPC (androgen ablation resistant prostate
cancer) phenotype [12]. The transcripts identified as dif-
ferentially expressed in our study exhibit similarities with
a previous study of AARPC tumors [10,12]. Cytokeratins
5 and 15 (KRT5/KRT15), markers of basal cells in prostate
glands, show uniform downregulation in all metastatic
tumors, confirming the absence of basal epithelial cells.
Biological annotation of differentially expressed genes in 
metastatic prostate cancer
The list of differentially expressed transcripts at least 2 fold
in all patients was further analyzed for biological themes
and gene ontology (GO) using the NIH's DAVID annota-
tion tool. This analysis revealed that metastatic prostate
cancer exhibits altered regulation of amino acid, carbohy-
drate and nucleotide metabolism consistent with the pro-
liferative capacity and altered energy needs of metastatic
tumors (data not shown). In the context of prostate cancer
biology, genes involved in cell-adhesion, bone remode-
ling, cell-cycle and transcription are of particular interest
(Table 4). Disruption of cell adhesion and altered interac-
tion with the extracellular matrix is a hallmark of meta-
static tumors [3]. In agreement with this, the secreted
phosphoprotein and cell adhesion molecule osteopontin
(SPP1) is one of the most highly upregulated transcripts
in our metastatic samples. Elevated expression of SPP1
has been correlated with poor prognosis in prostate
tumors and other cancers and it has often been implicated
in metastasis to bone and other organs [2,23-28]. In all 29
probe sets representing cell adhesion genes are altered in
all metastatic samples. This gene list includes FN1, ITGB8,
THBS2,  HNT  and  CDH10. Genes involved in bone
remodeling such as BMP4 and ANKH are also altered in
expression, although none of the samples in our study are
bone metastatic samples suggesting that these proteins
may also be involved in cancer metastasis to other organs.
Disruption of the cell cycle is highlighted by the presence
of a large number of cell-cycle related transcripts in the list
of differentially expresed genes in all metastatic samples.
The list contains 37 cell cycle genes, and includes SEP4,
SEP7, PTN and VEGF. Similarly, a large number of tran-
scription factors (67) including AR, SRY, FOS and EGR3,
are differentially expressed. Two members of the winged-
helix family of transcription factors, FoxP1 and FoxM1,
show upregulation in the metastatic samples. Interest-
ingly, FoxM1b has been shown to promote progression of
prostate carcinomas in an experimental model [29].BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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Table 2: Top 100 genes differentially expressed in metastatic samples compared to primary tumor samples
Gene Symbol Probe_ID d_Value Fold Change
EIF1A 34278_at 19.46 3.56
AR 1577_at 16.04 10.09
AK3 48822_s_at 15.18 3.03
EIF1A 663_at 14.17 2.69
PABPC1 44806_at 14.17 3.57
--- 45092_at 13.16 3.66
HSPD1 37720_at 12.80 2.80
--- 54219_at 12.78 3.23
LCHN 58324_at 12.39 3.49
MLL5 58271_at 12.15 2.45
--- 59350_at 11.98 3.22
--- 49558_at 11.93 2.73
LARP 41829_at 11.60 3.14
IBTK 52482_at 11.41 3.30
GIT1 43805_f_at 11.41 2.49
--- 56056_at 11.31 2.64
FLJ20736 64662_at 11.21 4.32
AR 1578_g_at 11.20 6.19
RALA 39253_s_at 11.19 3.61
HN1 56429_g_at 11.17 2.89
--- 54236_at 11.04 3.82
HSPCA 32316_s_at 10.94 2.68
NUCKS 59778_f_at 10.93 2.44
SOD1 36620_at 10.87 2.16
K-ALPHA-1 32272_at 10.72 2.23
--- 46558_at 10.70 4.70
--- 33207_at 10.62 2.25
VPS28 43061_i_at 10.61 2.19
BASP1 32607_at 10.57 4.15
CBX4 51842_at 10.49 3.06
--- 43680_at 10.45 4.85
GRB2 33855_at 10.44 2.55
--- 63147_at 10.43 3.86
UGT2B15 63915_f_at 10.35 3.07
METTL2 48730_s_at 10.26 2.24
--- 59101_at 10.11 7.12
MLL5 58690_at 10.02 2.24
G3BP 41133_at 10.00 2.25
AK3 32331_at 9.96 2.31
H2AV 39092_at 9.92 3.25
SDCCAG3 43014_at 9.91 6.04
FLJ10613 59989_s_at 9.82 2.20
YY1 891_at 9.70 2.08
--- 49326_at 9.59 2.20
--- 42646_at 9.50 5.45
LOC90462 54342_at 9.44 4.55
--- 55393_at 9.42 3.51
DDX17 41260_at 9.35 4.97
--- 63115_at 9.34 3.07
--- 57160_at 9.34 2.11
ETR101 36097_at -6.98 -3.85BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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MAGED2 34859_at -7.00 -2.22
--- 50411_at -7.00 -3.57
MGC4342 48094_at -7.01 -2.22
HT023 43461_g_at -7.01 -2.78
SFRP1 32521_at -7.02 -6.25
CRYL1 56407_at -7.04 -2.04
REA 37364_at -7.05 -2.17
ARL5 59499_at -7.08 -2.50
NY-REN-45 57833_s_at -7.09 -2.08
POMT1 46723_at -7.12 -3.23
MRC2 63996_at -7.13 -2.38
B3GALT3 53879_at -7.16 -3.13
NR4A1 280_g_at -7.21 -7.14
MUM2 65822_at -7.23 -2.38
LOC113246 46712_at -7.31 -2.17
GLTSCR2 61109_at -7.33 -2.44
FLJ20542 50164_at -7.36 -3.13
APCDD1 56272_at -7.42 -2.70
AIM1 32112_s_at -7.45 -3.70
FOS 1916_s_at -7.51 -7.69
FOS 1915_s_at -7.56 -9.09
PILB 43370_at -7.56 -2.08
C20orf178 45298_at -7.59 -2.13
B3GAT1 65859_at -7.60 -2.13
FLJ10283 46261_at -7.68 -2.27
RAB34 45269_at -7.71 -10.00
FLJ20069 61701_at -7.71 -3.23
PYGB 59669_at -7.77 -2.70
RPS27L 56410_at -7.80 -2.27
TOMM20 36198_at -7.91 -2.13
--- 43819_g_at -7.91 -3.13
STAT6 41222_at -7.92 -2.78
SELM 64449_at -7.95 -9.09
BOC 52999_at -8.15 -4.17
--- 44746_at -8.20 -2.13
SMBP 46307_at -8.28 -3.23
WNT5B 61330_at -8.34 -3.33
FLJ22386 50198_at -8.43 -4.55
WNT5B 58787_at -8.61 -2.27
ZDHHC4 45807_at -8.81 -2.13
YF13H12 36170_at -8.84 -2.08
HPIP 38063_at -9.04 -2.33
ANXA11 55664_at -9.16 -2.94
WNT5B 66142_s_at -9.33 -4.17
WAS 38963_i_at -9.43 -2.50
JFC1 44820_f_at -9.45 -3.33
JFC1 48805_f_at -9.48 -2.44
WNT5B 61292_s_at -9.86 -7.14
CIRBP 39864_at -10.94 -3.70
Gene expression data from the Affymetrix platform for 25 metastatic and 64 primary tumor samples was analyzed for differential gene expression 
by SAM. The differentially expressed genes with the lowest FDR were sorted by fold change. The top 100 genes, organized by fold change are 
shown.
Table 2: Top 100 genes differentially expressed in metastatic samples compared to primary tumor samples (Continued)BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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Box plots of gene expression values for selected genes in donor prostate samples, primary prostate cancer and metastatic  prostate samples Figure 1
Box plots of gene expression values for selected genes in donor prostate samples, primary prostate cancer and metastatic 
prostate samples.BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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The MAP kinase signaling pathway was also identified as
being important in the metastatic process, with 26 probe
sets involved in this pathway being differentially
expressed in all metastatic samples. The regulated genes
include  DUSP1,  DUSP2,  DUSP8,  MAP3K8,  MAP4K4,
FGF13, FGFR2 and FOS. Involvement of MAP kinase in
androgen receptor signaling has been previously
described [30].
Validation of differentially expressed transcripts with an 
independent set of primary tumors and different gene 
expression platforms confirms gene expression profiles of 
metastatic prostate cancer
Gene expression analysis with the CodeLink Uniset 20 K
microarray was carried out for 23 of the metastatic sam-
ples and compared to an independent set of 10 primary
tumors. Similar to the Affymetrix analysis (see above),
hierarchical clustering of the CodeLink data set reveals
heterogeneity in expression and no organ-specific cluster-
ing (data not shown). Comparison of results with the
Affymetrix based dataset, based on genes with common
Unigene ids on both platforms, show a similar pattern of
differentially expressed genes. Of the top 1000 up and
down regulated transcripts from each platform, approxi-
mately 70% share common unigene ids and of these 22%
of the genes are identified as regulated by both platforms
(see Additional file 3). This level of correlation is signifi-
cant, given the well-documented difficulties in cross-plat-
form comparisons of expression data [31,32]. Examples
of z-transformed expression values for selected genes in
both platforms are shown in Figure 3.
Additionally, real-time quantitative PCR (QPCR) assays
were performed for a selected set of genes in pooled sam-
ples for each patient with metastatic disease and 5 of the
primary tumors from the CodeLink set. The transcripts for
this analysis were chosen to represent diverse biological
processes and were chosen from the differentially
expressed genes identified as up/down-regulated in the
Affymetrix/Codelink data comparison. As shown in Fig-
ure 4, qPCR assays confirmed the results from the micro-
array platforms. SYNPO2  and  EGR3, which are
downregulated and RDX and FOXM1, which are upregu-
lated in the microarray analysis exhibit a very similar
expression pattern in the qPCR analysis. Interestingly,
FoxM1  is consistently upregulated in metastases, while
RDX was upregulated in only two of the four patients with
metastatic disease, confirming the heterogeneity of meta-
static prostate cancer.
Discussion
Despite extensive research, the molecular mechanisms of
metastatic prostate cancer and androgen resistance devel-
opment are still poorly understood. Our study shows that
a number of biological processes including cell adhesion,
cell cycle and transcription regulation are altered in meta-
static disease when compared to primary tumors, and
point to specific transcripts that participate in the meta-
static process.
Previous investigators have reported differences in gene
expression profiles of metastatic and primary prostate
cancer [10,12,14,21]. Our results show partial overlap
with these previous characterizations of metastatic dis-
ease. Some genes that are in concordance with these stud-
ies include transcription factors such as FOXM1, and c-
FOS.1. Differences in patient demographics, pathology
and treatment, non-standard tissue handling, experimen-
tal and statistical methods may all contribute to differ-
ences in gene lists. Differences with other published gene
lists might also reflect the fact that in our study, only sam-
ples from patients with androgen-insensitive prostate can-
cer were used. Additionally, in our experimental design
we have incorporated features that increase the signifi-
cance of our findings and increase the likelihood that the
genes identified truly reflect the biology of metastatic
Hierarchical clustering of primary and metastatic prostate cancer samples Figure 2
Hierarchical clustering of primary and metastatic prostate cancer samples. The 24 metastatic (Mets P1, Mets P2, 
Mets P3 and Mets P4) and 64 primary tumor samples were clustered. The top row of color coded boxes represents metastatic 
or primary samples; the bottom row represents the organ from which the sample was obtained.BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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Table 3: Transcripts with median values with at least 3 fold difference between metastatic and primary tumor samples
Gene Symbol Probe_ID P1 P2 P3 P4
Upregulated Transcripts
HBB 32052_at 22.37 5.78 13.25 56.28
SPP1 34342_s_at 24.16 26.78 4.75 5.39
HBA1///HBA2 31525_s_at 15.14 4.47 13.65 108.11
LGR4 43585_at 7.39 7.43 20.89 24.82
AR 1577_at 14.35 12.97 12.24 14.78
PRO1073 49666_s_at 4.56 13.25 10.01 13.5
UTRN 42646_at 10.11 6.02 12.11 16.31
HNT 59070_at 5.37 9.69 12.08 13.67
SDCCAG3 43014_at 7.99 8.57 11.24 17.32
LOC64744 42739_at 7.3 9.64 9.57 14.51
--- 1089_i_at 5.06 4.14 12.12 22.01
SPP1 2092_s_at 14.05 12.94 3.35 4.07
UBE2H 58777_at 9.5 7.45 6.55 15.13
SRPK1 63687_at 6.06 4.36 10.61 12.82
NCK2 33003_at 5 9.14 8.5 7.34
HIST1H3H 36757_at 7.26 17.07 8.47 5.61
PPP4R2 48663_at 5.09 6.97 8.59 16.16
C8orf16 47339_at 6.54 8.15 9.53 7.39
--- 55943_at 3.41 7.47 15.31 8.01
--- 64642_s_at 8.25 6.42 7.04 10.6
EP400 47518_at 5.94 9.27 4.51 9.32
GOLT1A 45144_at 3.9 6.17 8.37 12.32
--- 52853_g_at 9.83 7.1 6.25 7.03
LOC284058 44791_at 8.25 10.17 4.55 5.86
DAPK1 51580_at 3.42 6.04 8.03 11.32
NFATC2IP 38864_at 3.26 4.83 9.58 9.19
SEL1L 40689_at 4.71 7.84 6.13 10.94
TM4SF9 47746_at 3.43 6.26 8.92 7.52
MLLT2 65205_at 3.43 7.13 6.57 13.01
SC4MOL 46802_at 22.91 7.35 5.62 6.17
--- 62671_at 6.38 7.13 5.74 11.03
BIRC6 46558_at 5.67 8.59 7.5 5.92
MAP4K4 51474_at 4.86 4.32 8.7 8.52
MLLT2 53300_at 4.65 3.99 9.39 8.1
--- 52851_at 8.71 5.94 6.35 6.25
MRRF 51635_at 4.23 4.87 7.39 8.23
ACAS2 62783_at 4.29 6.14 7.02 5.9
--- 60658_at 3.4 6.84 5.19 9.1
SUMO1 49551_at 4.05 7.2 4.77 7.75
AR 1578_g_at 7.56 4.86 5.32 6.37
GALNT7 59101_at 8.41 4.12 5.11 6.54
GPR75 44203_at 5.14 8.32 3.9 6.31
TBL1XR1 65001_r_at 3.53 12.3 4.06 7.19
HSD17B12 43292_at 4.74 8.88 3.64 6.28
MRPS28 43095_at 5.79 5.39 5.58 5.14
FN1 64719_at 27.07 6.02 4.05 4.93
GPR158 44214_at 7.21 3.33 4.32 6.62
--- 48069_at 6.27 9.88 3.38 4.55
FLJ21657 58778_at 4.34 5.6 6.17 5.18
MLL5 43301_at 4.76 3.61 5.87 10.34
--- 55761_at 3.78 4.88 5.65 6.93BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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DLG1 47231_at 3.4 4.77 6.22 5.7
MYO5B 63281_r_at 3.29 6.17 4.29 6.84
--- 49268_at 3.55 19.86 3.61 6.75
FUS 43501_at 3.93 3.78 6.42 8.97
CCDC35 54684_at 4.9 8.14 3.55 5.43
--- 43435_at 6.85 4.83 4.82 5.49
SMA4 32921_at 4.68 5.53 5.74 4.26
NCOA1 45953_at 6.53 4.13 3.58 6.06
S100A8 41096_at 4.22 5.89 3.8 22.58
PRKCBP1 53493_at 4.65 7.37 4.5 5.35
RNPC2 65083_at 3.18 3.96 6.01 9.19
CAMSAP1 62630_at 4.45 5.8 3.36 5.36
EEF1G 41903_at 5.19 4.58 4.31 5.34
EIF5 51379_at 3.44 4.08 5.62 11.07
MAML3 49879_at 3.39 3.22 10.27 5.87
C21orf106 59651_at 3.19 4.02 5.23 6.44
VCIP135 42715_at 3.37 3.61 5.52 8.55
FOXO3A 55502_at 3.48 4.37 6.97 4.74
C7orf20 49143_s_at 4.23 4.62 4.41 5.78
GNMT 46482_at 3.59 4.84 4.24 4.64
DONSON 48549_at 4.1 3.58 4.66 5.28
--- 43436_g_at 4.98 3.75 3.58 5.09
PKP4 66327_at 3.31 3.88 4.56 6.2
PCBP2 55393_at 3.73 3.19 4.36 6.29
CPEB4 57169_at 3.7 3.92 4.14 4.48
CUGBP1 34683_at 4.26 3.76 3.13 4.78
FALZ 47458_at 4.21 3.65 3.82 4.09
--- 51586_at 3.51 4 4.99 3.89
RALA 39253_s_at 3.92 4.3 3.29 3.85
MLL5 45092_at 4.36 3.21 4.48 3.39
PABPC1 44806_at 3.74 3.98 4.2 3.07
EIF1AX 34278_at 3.99 3.47 3.84 3.19
C7orf2 42173_at 3.15 3.27 5.07 4.04
--- 63147_at 3.25 5.4 3.12 4.04
RAD23B 41157_at 3.2 3.46 3.64 4.45
--- 61037_at 3.44 3.56 3.47 3.73
NFATC1 39143_at 3.13 3.21 9.06 3.78
JARID1A 50532_at 3.22 3.32 3.54 4.12
PDLIM5 37366_at 3.02 3.58 3.42 3.16
Downregulated Transcripts
NEFH 33767_at -117.15 -147.36 -9.9 -17.18
C10orf116 32527_at -35.49 -29.63 -46.85 -66.5
KLK11 40035_at -23.65 -19.24 -39.73 -62.15
FAM3B 59657_at -15.81 -27.92 -26.09 -25.97
PGM5 52140_at -23.87 -26.5 -44.27 -17.72
MRGPRF 52946_at -15.61 -18.57 -30.59 -70.95
KRT15 37582_at -21.85 -20.74 -19.22 -33.68
PTN 34820_at -11.62 -31.95 -10.24 -27.11
SELM 64449_at -6.36 -8.4 -29.23 -39.36
MYLK 46276_at -5.87 -15.22 -22.57 -20.86
SYNPO2 50361_at -15.14 -15.77 -20.15 -84.14
KRT5 613_at -13.21 -11.12 -22.66 -32.96
FOS 2094_s_at -10.72 -25.75 -13.72 -16.45
PKP1 51214_at -11.57 -16.34 -11.83 -17.85
Table 3: Transcripts with median values with at least 3 fold difference between metastatic and primary tumor samples (Continued)BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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--- 42921_at -9.96 -11.67 -15.61 -16.5
RAB34 45269_at -14.36 -11.54 -17.49 -10.35
--- 48927_at -10.61 -14.93 -8.77 -21.91
ALOX15B 37430_at -12.47 -12.41 -14.17 -9.1
FOS 1915_s_at -7.59 -26.38 -11.03 -12.11
TMEM16G 62387_at -9.63 -13.32 -12.59 -9.93
--- 64676_at -17.3 -9.39 -6.32 -13.05
SFRP1 32521_at -13.1 -5.73 -8.29 -16.73
NDFIP2 60510_at -7.2 -9.23 -11.72 -15.15
FHOD3 50298_at -9.96 -12.84 -5.59 -10.96
WNT5B 61292_s_at -8.72 -11.85 -5.42 -13.92
SYNPO2 48039_at -11.04 -8.8 -12.64 -9.34
BOC 64423_s_at -3.63 -8.16 -11.8 -54.66
SLC20A2 1137_at -9.27 -5.08 -10.51 -12.61
COL8A2 52652_g_at -7.95 -9.99 -11.56 -9.75
--- 52678_at -9.69 -9.99 -3.76 -17.93
FOS 1916_s_at -7.58 -21.81 -6.93 -11.58
ARGBP2 51939_at -7.77 -13.86 -10.4 -8.71
CTGF 64342_at -4.21 -4.15 -20.44 -14.87
EPHB6 39930_at -8.61 -9.66 -8.32 -19.41
SYNPO2 60532_at -9.77 -5.54 -8.77 -9.03
NR4A1 280_g_at -8.68 -13.49 -5.82 -8.58
DKFZP564O0823 54033_at -4.67 -3.72 -11.83 -20
GSTO2 45609_at -4.73 -6.81 -9.6 -16.18
--- 49321_at -7.91 -8.41 -9.24 -3.88
EGR3 40375_at -9.89 -7.71 -8.49 -6.44
SYNPO2 61681_at -7.85 -8.33 -4.56 -18.57
PI15 58361_at -3.59 -4.26 -12.77 -11.74
FOSB 36669_at -8.81 -6.27 -7.6 -8.39
OGN 43507_g_at -3.56 -8.26 -7.19 -25.54
MOXD1 36834_at -5.4 -11.7 -10 -3.85
LSAMP 43930_at -3.05 -7.62 -9.76 -7.67
EGR2 37863_at -7.7 -5.52 -7.23 -15.41
DKFZp686D0853 49770_at -10.18 -7.66 -7.16 -4.39
LGP1 52826_at -13.75 -5.94 -3.83 -8.11
ME3 35216_at -7.45 -9.26 -6.54 -5.32
PPP1R14A 58774_at -6.68 -6.14 -7.31 -7.87
FLJ22386 50198_at -6.8 -3.64 -6.98 -6.65
NR4A1 279_at -5.31 -8.04 -5.11 -8.48
WFDC1 64111_at -3.79 -11.21 -6.64 -6.66
ZFP36 40448_at -6.39 -6.86 -7.25 -3.61
CACHD1 43554_at -6.68 -3.34 -17.46 -6.57
RLN1 35070_at -6.78 -11.78 -5.14 -6.39
--- 49975_at -6.43 -6.16 -6.74 -10.11
CYBRD1 65852_at -6.43 -4.79 -6.7 -7.23
PER3 53766_at -15.43 -6.79 -5.56 -6.29
MN1 37283_at -4.47 -7.36 -5.55 -7.48
DNCI2 35788_at -4.2 -8.68 -3.02 -10.64
MRVI1 43966_at -6.76 -5.28 -12.19 -6.09
AZGP1 35834_at -6.32 -3.86 -38.18 -6.18
MGC14839 48949_at -8.96 -4.19 -8.25 -3.61
SMTN 64499_s_at -5.2 -15.22 -7.18 -4.42
HSPC157 50179_at -5.66 -3.18 -6.63 -8.09
WFDC2 33933_at -5.3 -6.5 -5.73 -6.81
BTG2 36634_at -6.99 -3.13 -9.25 -5.22
Table 3: Transcripts with median values with at least 3 fold difference between metastatic and primary tumor samples (Continued)BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
Page 13 of 21
(page number not for citation purposes)
AXIN2 64129_at -4.97 -6.97 -7.18 -4.2
PDGFC 45217_at -4.32 -7.53 -8.81 -3.97
MLLT10 63345_at -7.2 -5.85 -5.9 -3.84
BMP7 49273_g_at -4.58 -4.89 -6.82 -13.13
MCC 49504_r_at -5.9 -5.71 -5.08 -5.84
HEXA 39340_at -8.15 -5.65 -4.18 -5.88
GSTT2 1099_s_at -6.47 -5.05 -6.8 -4.66
SSPN 65647_at -5.4 -5.88 -3.12 -17.61
UPK3A 36379_at -5.37 -4.71 -5.81 -6.91
PDE5A 54668_at -4.44 -5.17 -5.87 -9.56
PSD3 63832_at -3.19 -6.04 -4.98 -6.58
ALDH7A1 61965_at -5.85 -5.14 -5.88 -3.13
FMOD 33431_at -7.62 -4.3 -4.9 -6.04
TSPAN2 53693_at -6.38 -4.49 -4.54 -6.77
DKFZP586H2123 40017_at -6.52 -6.49 -4.32 -3.91
EFS 33883_at -5.43 -3.58 -6.35 -5.18
PODN 63953_at -4.16 -5.3 -4.84 -4.98
DUSP1 1005_at -6.53 -16.66 -3.02 -3.19
SLC22A17 58898_s_at -4.93 -5.81 -4.66 -4.44
CDH10 47535_at -4.87 -3.19 -8.27 -4.65
--- 64163_at -3.66 -5.03 -4.79 -4.7
--- 42587_at -4.68 -4.62 -4.9 -3.45
TSPAN2 57331_at -4.44 -8.06 -3.42 -4.71
SORBS1 56409_at -5.45 -5.7 -3.17 -3.53
C21orf63 50658_s_at -4.54 -3.36 -4.15 -5.31
NBL1 37005_at -3.34 -4.27 -4.31 -6.36
CIRBP 39864_at -4.38 -3.53 -4.19 -6.8
KLF4 48587_at -3.77 -3.62 -4.57 -12.5
ZCSL2 45320_at -3.1 -3.19 -5.88 -5.13
C12orf10 53911_at -3.62 -4.44 -3.86 -6.46
CERKL 60314_at -4.68 -3.03 -7.37 -3.62
NOV 39250_at -3.2 -3.9 -4.38 -7.37
EPB41L5 60293_at -4.33 -4.97 -3.06 -3.92
WNT5B 66142_s_at -3.94 -3.87 -4.49 -4.16
ACYP2 64090_s_at -3.36 -4.33 -3.68 -5.82
C9orf103 56186_at -3.14 -4.62 -4.03 -3.73
FBXO2 57811_at -3.51 -3.37 -4.16 -5.33
CD38 40323_at -3.25 -3.37 -4.27 -4.27
BCAS1 37821_at -4.96 -3.19 -4.26 -3.34
TMSL8 36491_at -3.03 -4.11 -3.45 -7.67
ISL1 39990_at -3.12 -3.78 -3.61 -3.91
HSPB8 56474_at -3.45 -3.87 -3.04 -7.5
B3GALT3 53879_at -3.04 -4.02 -3.77 -3.48
CYBRD1 50955_at -3.7 -3.51 -3.21 -5.6
EFEMP2 63644_at -3.25 -3.91 -3.28 -3.97
TU3A 45260_at -3.14 -3.94 -3.22 -4.82
LOC57228 34176_at -3.68 -5.3 -3.41 -3.16
IER2 36097_at -4.79 -3.2 -3.11 -3.88
DKFZP564K1964 65860_at -3.53 -3.11 -3.52 -4.62
A patient-specific median expression value was calculated from the multiple samples for each patient. These median values were then compared to 
the primary tumor expression value and those genes with 3-fold difference between metastatic and primary prostate cancer is shown.
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Table 4: GO and pathway annotation of genes and pathways altered in metastatic prostate cancer
Probe ID Gene Symbol Overall FC FC_P1 FC_P2 FC_P3 FC_P4
Bone remodeling
34342_s_at SPP1 24.7 24.16 26.78 4.75 5.39
2092_s_at SPP1 11.8 14.05 12.94 3.35 4.07
47958_r_at ANKH -2 -2.23 -2.31 -2.03 -3.66
65035_at TF1P11 -2.31 -2.28 -2.63 -2.97 -3.77
44596_at TWIST2 -2.45 -2.7 -2.12 -2.94 -2.35
40333_at BMP4 -2.5 -2.86 -2.89 -3 -5.23
49273_g_at BMP7 -2.81 -4.58 -4.89 -6.82 -13.13
Cell Adhesion
34342_s_at SPP1 24.7 24.16 26.78 4.75 5.39
2092_s_at SPP1 11.8 14.05 12.94 3.35 4.07
64719_at FN1 7.5 27.07 6.02 4.05 4.93
59070_at HNT 5 5.37 9.69 12.08 13.67
62628_at PCDHGC3 3.4 2.24 5.44 2.97 2.42
44892_at MLLT4 3.3 2.63 2.07 6.21 7.48
47064_at HNT 3.27 2.98 4.37 8.07 8.4
66327_at PKP4 2.79 3.31 3.88 4.56 6.2
35246_at TYRO3 2.4 -5.43 -3.58 -6.35 -5.18
659_g_at THBS2 1.9 2.39 2.37 2.26 2.7
59623_at PCDH18 -2.22 -2.09 -2.89 -2.17 -2.39
53497_at ITGB8 -2.38 -2.88 -2.69 -3.51 -13.81
60876_at COL8A2 -2.38 -2.26 -3.26 -3.61 -2.25
47007_s_at NINJ2 -2.63 -2.55 -3.4 -3.3 -5.93
103_at THBS4 -2.7 -2.02 -3.37 -2.16 -3.26
46520_at ROBO2 -2.86 -2.58 -4.96 -4.14 -4.46
45939_at CNTN3 -3.33 -3.38 -2.14 -7.41 -11.94
47535_at CDH10 -3.7 -4.87 -3.19 -8.27 -4.65
56192_at PCDH7 -3.7 -2.5 -5.33 -5.74 -3
52999_at BOC -4.17 -2.42 -8.8 -12.25 -6.16
43930_at LSAMP -4.35 -3.05 -7.62 -9.76 -7.67
33883_at EFS -4.76 -5.43 -3.58 -6.35 -5.18
64342_at CTGF -5.26 -4.21 -4.15 -20.44 -14.87
64423_s_at BOC -6.67 -3.63 -8.16 -11.8 -54.66
52652_g_at COL8A2 -10 -7.95 -9.99 -11.56 -9.75
51214_at PKP1 -14.29 -11.57 -16.34 -11.83 -17.85
52140_at PGM5 -25 -23.87 -26.5 -44.27 -17.72
Cell_cycle
47231_at DLG1 3.57 3.4 4.77 6.22 5.7
45574_g_at TPX2 3.49 11.09 2.57 3.24 8.6
54219_at 7-Sep 3.23 3.3 2.79 2.17 3.27
53998_at CLASP2 3.09 2.67 2.84 4.18 4.13
37933_at RBBP6 3.08 2.27 5.42 7.52 8.79
53568_at 7-Sep 2.97 3.94 2.4 3.53 2.49
51815_at TERF1 2.54 2.11 4.78 5.1 3.51
1797_at CDKN2D 2.41 3.65 2.76 2.46 2.47
50084_at DNCH1 2.29 2.42 2.15 2.11 2.29
66955_at EML4 2.13 2.22 3.3 6.8 5.09
1833_at CDK2 2.12 3.14 2.56 2.05 2.45
52744_at HRPT2 2.07 2.73 2.62 3.4 3.36
60568_at BCL2 2.07 2.18 3.27 3.35 3.75
41632_at E2F3 2.05 2.34 2.04 2.2 2.15
59821_at BCL2 1.87 2.89 3.13 3.58 3.86
36101_s_at VEGF 1.53 2.5 2.38 2.53 3.06BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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63158_at GRLF1 1.27 3.55 2.63 2.3 3.45
65908_at CHES1 -2.1 -3.3 -2.11 -2.34 -5.51
46664_at PYCARD -2.14 -2.36 -2.06 -2.94 -2.08
48980_at ZAK -2.25 -2.02 -4.8 -2.06 -2.07
36838_at KLK10 -2.38 -3.38 -2.94 -2.07 -6.13
50199_s_at RGC32 -2.73 -2.49 -3.64 -5.45 -4.17
39780_at PPP3CB -2.74 -3.82 -2.36 -3.06 -2.85
33864_at ZMYND11 -2.78 -4.77 -2.85 -3.79 -3.79
49504_r_at MCC -3.45 -5.9 -5.71 -5.08 -5.84
37005_at NBL1 -3.83 -3.34 -4.27 -4.31 -6.36
234_s_at PTN -3.86 -2.92 -5.02 -2.15 -3.33
37283_at MN1 -4.63 -4.47 -7.36 -5.55 -7.48
45217_at PDGFC -4.82 -4.32 -7.53 -8.81 -3.97
1005_at DUSP1 -6.16 -6.53 -16.66 -3.02 -3.19
36669_at FOSB -7.85 -8.81 -6.27 -7.6 -8.39
34820_at PTN -12.55 -11.62 -31.95 -10.24 -27.11
37430_at ALOX15B -21 -12.47 -12.41 -14.17 -9.1
Transcription
1577_at AR 10 14.35 12.97 12.24 14.78
65001_r_at TBL1XR1 7 3.53 12.3 4.06 7.19
1578_g_at AR 6.18 7.56 4.86 5.32 6.37
42733_i_at FOXP1 5.6 2.61 5.92 14.54 14.09
52769_at POLR2A 5.1 2.93 4.04 12.61 11.14
54342_at ZNF605 4.55 2.75 6.89 4.85 4.04
65083_at RNPC2 4.1 3.18 3.96 6.01 9.19
42734_r_at FOXP1 3.5 2.01 4.49 7.53 8.6
48423_at ZNF621 3.4 2.11 8.51 3.74 7.33
51543_at ZNF395 3.32 2.99 5.52 6.73 6.51
44546_at ZNF148 3 3.32 2.59 4.72 4.18
49633_at HES6 3 5.76 2.26 2.34 6.72
51842_at CBX4 3 3.32 2.61 5.21 3.08
54981_r_at SFPQ 3 2.27 4.87 4.9 5.33
60076_at SOX4 3 3.32 3.77 2.09 2.72
43580_at MORF4L2 2.93 2.42 3.49 3.38 6.52
34715_at FOXM1 2.84 6.82 2.17 2.9 2.99
40674_s_at HOXC6 2.81 3.09 2.48 6.67 4.56
56981_at ZKSCAN1 2.77 2.65 2.4 2.6 4.04
55293_at ADNP 2.73 2.44 3.6 3.98 3.9
43545_at ZNF281 2.7 2.17 3.21 3.05 4.19
32653_at BRD8 2.56 2.11 3.73 3.22 4.45
53846_at FLJ21616 2.55 3.1 2.96 5.41 5.92
45953_at NCOA1 2.42 6.53 4.13 3.58 6.06
46006_at ERCC8 2.35 2.35 2.7 3.36 5.84
50911_at RLF 2.35 2.18 2.38 4.07 4.92
58641_at MAML3 2.33 2.86 2.31 5.61 5.44
42571_at MORF4L2 2.32 2.21 3.7 3.99 3.48
43120_at MLL3 2.32 2.55 2.48 2.14 2.74
31437_r_at ESR2 2.3 2.06 3.06 3.13 4.09
50532_at JARID1A 2.3 3.22 3.32 3.54 4.12
44939_at MLL3 2.22 2.55 2.48 2.14 2.74
55502_at FOXO3A 2.21 2.44 3.6 3.98 3.9
52328_at SP3 2.2 2.13 2.62 3.38 3.11
54220_r_at NLK 2.16 2.39 4.23 3.94 4.41
41632_at E2F3 2.04 2.34 2.04 2.2 2.15
66313_at HIPK1 2 2.09 2.85 2.95 3.98
42193_r_at --- 1.9 2.16 2.04 2.66 3.29
Table 4: GO and pathway annotation of genes and pathways altered in metastatic prostate cancer (Continued)BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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39540_at ZBTB7A 1.89 2.42 3.27 3.03 2.61
63158_at GRLF1 1.79 3.55 2.63 2.3 3.45
65908_at CHES1 -2.13 -3.3 -2.11 -2.34 -5.51
36770_at STAT2 -2.17 -2.3 -3.47 -2.82 -3.75
64963_at EYA4 -2.17 -3.06 -3.31 -2.55 -5.01
65945_at PNRC2 -2.17 -2.08 -2.26 -2.61 -2.24
1454_at SMAD3 -2.27 -2.17 -2.51 -2.02 -2.07
54658_at PSPC1 -2.33 -3.18 -2.22 -3.63 -13.16
44596_at TWIST2 -2.5 -2.7 -2.12 -2.94 -2.35
46704_at KLF3 -2.63 -2.38 -2.29 -2.19 -3.33
51253_at ZBTB4 -2.63 -2.92 -3.18 -2.63 -3.93
287_at ATF3 -2.78 -2.11 -2.33 -2.63 -3.3
33864_at ZMYND11 -2.78 -4.77 -2.85 -3.79 -3.79
63526_f_at KLF6 -2.78 -3.21 -2.48 -2.71 -3.33
64932_at VPS36 -2.86 -4.56 -2.88 -2.48 -2.27
45680_at ZNF537 -2.94 -2.77 -3.37 -2.78 -3.74
43431_at SOX2 -3.03 -2.09 -3.8 -7.43 -7.34
47620_at XAB2 -3.33 -2.7 -8.25 -7.6 -8.49
465_at HTATIP -3.45 -2.52 -2.37 -4.49 -2.47
37863_at EGR2 -4.55 -7.7 -5.52 -7.23 -15.41
48587_at KLF4 -4.76 -3.77 -3.62 -4.57 -12.5
36634_at BTG2 -5.26 -6.99 -3.13 -9.25 -5.22
279_at NR4A1 -6.25 -5.31 -8.04 -5.11 -8.48
280_g_at NR4A1 -7.14 -8.68 -13.49 -5.82 -8.58
40375_at EGR3 -8.33 -9.89 -7.71 -8.49 -6.44
53766_at PER3 -9.09 -15.43 -6.79 -5.56 -6.29
MAP Kinase Pathway
1562_g_at DUSP8 5.8 2.42 5.01 16.6 5.86
1104_s_at HSPA1A/HSPA1B 4.1 7.81 2.77 2.81 5.02
51474_at MAP4K4 3.57 4.86 4.32 8.7 8.52
60658_at --- 3.5 -3 -2.96 -3.6 -3.73
50375_at SOS1 3 2.97 4.08 4.57 3.79
33855_at GRB2 2.55 2.29 2.61 3.85 2.1
42838_f_at MAP3K8 2.3 2.25 3.4 2.78 2.08
54220_r_at NLK 2.16 2.39 4.23 3.94 4.41
790_at NGFB 1.86 2.08 2.35 3.37 2.9
48980_at ZAK -2.27 -2.02 -4.8 -2.06 -2.07
43053_g_at PAK1 -2.7 -6.31 -2.46 -2.83 -2.11
39780_at PPP3CB -2.78 -3.82 -2.36 -3.06 -2.85
468_at FGF13 -2.78 -4.35 -4.35 -2.11 -2.56
65904_at --- -2.94 -2.05 -3.48 -4.18 -3.43
1292_at DUSP2 -3.13 -3.72 -3.66 -3.17 -2.19
57299_s_at RRAS -3.23 -3 -2.96 -3.6 -3.73
1970_s_at FGFR2 -5.56 -2.55 -13.13 -8.88 -4.92
1005_at DUSP1 -6.25 -6.53 -16.66 -3.02 -3.19
279_at NR4A1 -6.25 -5.31 -8.04 -5.11 -8.48
280_g_at NR4A1 -7.14 -8.68 -13.49 -5.82 -8.58
1916_s_at FOS -7.69 -7.58 -21.81 -6.93 -11.58
1915_s_at FOS -9.09 -7.59 -26.38 -11.03 -12.11
2094_s_at FOS -16.67 -10.72 -25.75 -13.72 -16.45
Genes whose median value shows at least 2 fold change in every metastatic patient were annotated by NIH's DAVID tool. Genes belonging to 
selected GO categories with a significant number of differentially expressed genes are shown. Overall_FC, the fold change in the mean expression 
value of all metastatic samples compared to the primary samples;FC_P1, FC_P2, FC_P3, FC_P4; a patient-specific median expression value was 
calculated using all the samples from each patient. This was compared to the median value for the primary tumors. Patient P4 had only sample and 
this was considered the median.
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Comparison of Z-transformed expression values between the Affymetrix and Codelink platforms Figure 3
Comparison of Z-transformed expression values between the Affymetrix and Codelink platforms. Gene expres-
sion data from Affymetrix and CodeLink experiments was Z-transformed to allow comparison. Data for selected differentially 
expression genes is shown.BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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prostate cancer. First, by subtracting transcripts previously
identified as being expressed by the prostatic stroma, we
have incorporated previous knowledge about the expres-
sion profiles of different components of prostate tumors
in order to focus on those transcripts intrinsic to meta-
static cells. This takes into account the fact that metastatic
tumors do not contain all the tissue elements present in
organ-confined tumors. The major benefit of this strategy
is to better define the genes that are down-regulated in
metastatic tumor cells. Second, by analyzing multiple
tumor samples from each patient, we have addressed the
fact that metastatic prostate cancer shows significant het-
erogeneity, even within the same patient [21]. This is cor-
roborated by our results. and we address this issue by
focusing our analysis on the transcripts that show signifi-
cant differential expression in all metastatic sites within
and between patients.
Multiple biological processes appear to be altered in met-
astatic prostate cancer. One common theme that has
emerged from studies of metastatic disease is the central
role of the androgen receptor in the development of
androgen resistant disease. Several mechanisms including
amplification of the AR  gene, upregulation of mRNA
expression to allow binding by low levels of androgens,
mutations in the ligand binding domain (LBD) that allow
the receptor to be activated by antagonists, and alteration
in the normal AR signaling pathway, have been proposed
Validation of differentially expressed genes with quantitative real time PCR Figure 4
Validation of differentially expressed genes with quantitative real time PCR. QPCR was performed on RNA from 
samples used in the CodeLink analysis. Three selected metastatic RNA samples from each patient were pooled together 
(except for patient FB666 n = 1) and therefore four RNA samples, each representing one metastatic patient and 5 primary 
tumors were tested. The insert shows average expression values for metastatic and primary tumors.BMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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to explain the ability of prostate cancer to recur in the
presence of androgen ablation therapy [33,34]. Consist-
ent with previous observations, AR is up-regulated in all
metastatic samples in our study. Similarly, gene expres-
sion changes of the MAP kinase pathway in metastasis
may be related to the development of the AARPC pheno-
type. The gene list from our analysis shares some similari-
ties with mouse xenograft prostate cancers models
(CWR22) of androgen independence. MSMB,  CCND1,
EFNA3, FKBP and ADM, HGF are similarly regulated in
mouse models and in our study [35-37].
Changes in the expression level of several additional tran-
scripts may reveal clues about the mechanism of metasta-
sis and androgen resistance. We find upregulation of the
enzyme UGT2B15 in all metastatic patients. Upregulation
of UGT2B15 in androgen independent prostate cancer has
been reported previously [14]. This increase appears para-
doxical, since UGT2B15 is involved in hormone inactiva-
tion. However, as suggested by Stanbrough et al [14],
upregulation of multiple genes related with androgen
metabolism might reflect that metastatic tumor cells have
an increased capacity to convert weak androgens into tes-
tosterone or DHT. However, in contrast to their findings,
transcripts for AKR1C3,  SRD5A1,  HSD3B2,  AKR1C2,
AKR1C1 are not consistently upregulated in the metastatic
samples in our study. Interestingly, when reviewing indi-
vidual values for each sample, some metastases indeed
show higher levels for some of these transcripts, which
might reflect the heterogeneity of metastatic prostate can-
cer phenotypes. Another possible explanation for this dis-
crepancy is that the metastatic samples used by
Stanbrough et al. are all from bone metastases and this
type of sample is not represented in our study. Clearly,
further investigation into the role of these pathway genes
in the development of androgen resistance by metastatic
samples is needed.
Several genes involved in cell-cell interaction and cell
adhesion appear to be up-regulated in these tumors. SPP1
(osteopontin), a secreted, integrin-binding glycoprotein
with adhesive properties, has been shown to be correlated
with metastasis to the bone and with poor prognosis in
various cancers and is highly upregulated in all the meta-
static samples in our study. Elevated plasma osteopontin
levels have also been correlated with lower survival and
bone metastasis in hormone resistant prostate cancer
[25]. Interestingly, Stanborough and collaborators also
identified SPP1 as upregulated in their metastatic sam-
ples, however, their interpretation was that this increase
was part of the bone response to the metastases. Our study
confirms that upregulation of SPP1 is a feature intrinsic to
androgen-resistant metastatic prostate cancer, independ-
ent of the site of metastasis. It has been postulated that
metastasis to specific target organs may require not only
expression of SPP1 but an additional set of signaling mol-
ecules that promote metastasis to the specific organ. SPP1
when expressed with IL11 has been shown to promote
metastasis of breast cancer cells to the bone [38] but not
to the adrenal medulla. Further detailed studies are
required to address the specific role of SPP1 and other co-
expressed genes in prostate cancer metastasis and whether
SPP1 represents a potential therapeutic target for andro-
gen-resistant disease. Interestingly, the gene expression
profile termed as "bone module" and postulated as a hall-
mark of tumor metastasis to bone [39] is not dysregulated
in our study, most likely reflecting the fact that we did not
assay bone metastatic samples. It is also possible, that the
role that SPP1 plays in metastasis to bone and/or other
organs may involve distinct mechanisms [38].
Metastatic tumors have been described as undergoing an
epithelial to mesenchymal transition with loss of the dif-
ferentiated phenotype. Downregulation of transcription
factors such as JUN has been observed in advanced stages
of other cancers and its loss of activity has been postulated
to be involved in this transition [40]. In our study, both
FOS and JUNB, which are upregulated in primary tumors
compared to normal prostate tissue are highly downregu-
lated in the metastatic samples. FBN, also representative
of the EMT transition [38] is overexpressed in our meta-
static samples. Our analysis has also identified a number
of additional genes, such as KLK11,STC1 and S100A8 that
are uniformly regulated in all metastatic patients. The role
of S100A8 in prostate cancer has been studied with evi-
dence suggesting that it is elevated in prostate cancer and
may be involved in MAP kinase and NFK-B  signalling
[41,42]. STC1, involved in calcium homeostasis, has been
reported to have osteoblastic and angiogenic modulator
properties with altered expression in some cancers [43-
45]. The serine protease KLK11 appears to be regulated in
prostate cancer with negative correlation between aggres-
siveness and expression [46].
A recent study observed overexpression of 62 genes due to
surgical manipulation related ischemia of the prostate
[47]. In our study, 12 out of the 62-gene ischemia profile
are downregulated in all metastatic samples. This gene list
includes  DUSP1,  BTG2,  IER2,  PTGS2,  NR4A1,  AMD1,
C20orf35, KLF4, RAB4A, KLF6, CTGF and GOLPH2. In our
data set, these genes represent only 0.01% of the total
number of genes differentially regulated in all metastatic
samples. Since our metastatic samples all originate from
autopsy studies, it is likely that they had been exposed to
longer ischemia than the organ confined samples
obtained from surgical specimens. Thus, if the differences
we observed were related to the ischemia, we would have
expected an increase in the expression of these genes, and
not the observed downregulation. Therefore, it is unlikelyBMC Cancer 2007, 7:64 http://www.biomedcentral.com/1471-2407/7/64
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that surgical manipulation can explain the differential
gene expression between metastatic and primary tumors.
Conclusion
In summary, our results support the roles for specific cell
adhesion, androgen metabolism and transcription factor
genes in the development of androgen-independent met-
astatic prostate cancer. Furthermore, the differentially
expressed transcripts in metastatic tumors that we report
have been validated with two independent sets of primary
tumors, two gene expression microarray platforms, and
selected genes were further validated by qRT-PCR. Our
results corroborate the notion that metastatic prostate
cancer is quite heterogeneous within a single patient.
Despite this heterogeneity our experimental design
allowed us to identify common expression profiles for
androgen-independent metastatic prostate cancer.
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